Biomarker-Driven Therapies and Immunotherapies in Non-Small Cell Lung Cancer

What is the Purpose of this Study?

This study focuses on patients with non-small cell lung cancer. The purpose is to study tumor tissue to determine whether a targeted or immunotherapy treatment will have an effect on specific genes and proteins in the patient’s tumor. The usual approach for individuals who are not in a study is treatment with chemotherapy or immunotherapy drugs. Patients in this study will be asked to submit a tumor sample, which will be tested for specific genes and proteins. Based on the test results, participants will be assigned to a treatment sub-study. The assignment will also depend which sub-studies are available when the participant is ready to receive treatment, and in some individuals, which sub-studies are available if the patient’s tumor begins to grow.


Eligibility

  • 5.1 Registration
  • Step 0:
  • 1. Patients who need the fresh biopsy must also submit whole blood for ctDNA testing (see Section 15.3). These patients must be registered to Step 0 to obtain a patient ID number for the submission.
Show more

Where can I participate?

  • Cedars-Sinai Cancer at Beverly Hills (THO)
  • Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC (CSMC Affiliate)
  • Cedars-Sinai Cancer at SOCC
  • Cedars-Sinai Cancer at Valley Oncology


More about this Clinical Trial

What is the full name of this clinical trial?

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

Study Details
Disease Type/Condition

Lung

Principal Investigator

Reckamp, Karen

Co-Investigators

Andrew Horodner, Barry Rosenbloom, David Chan, David Hoffman, Hugo Hool, Jeremy Lorber, Johnny Chang, Justin Wayne Tiulim, Kamya Sankar, Kevin Scher, Natasha Banerjee, Ryan Ponec, Swati Sikaria, Syed Jilani, Thomas Lowe, Vanessa Dickey

Age Group

Adult

Phase

N/A

IRB Number

STUDY00000723

ClinicalTrials.gov ID

NCT03851445

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Lung

Principal Investigator

Reckamp, Karen

Age Group

Adult

Phase

N/A

IRB Number

LUNGMAP

ClinicalTrials.gov ID

NCT03851445

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org